Can a Rat Plasma Amphetamine Level Predict Attention or Impairment? What Eleven Rats Actually Showed

Short answer: Not for an individual human. A controlled rat experiment found that injected d-amphetamine could improve or disrupt a particular attention task depending on dose and elapsed time. A separate group of rats supplied chemically measured plasma concentrations, with reported concentrations of approximately 44–102 ng/mL during times associated with improved task accuracy. The study did not measure drug concentration and performance in the same animals, did not test human venous whole blood, and did not validate an impairment or safe-driving threshold for anyone.

The underlying original experiment is Slezak, Mueller, Ricaurte, and Katz, Pharmacokinetic and pharmacodynamic analysis of d-amphetamine in an attention task in rodents, Behavioural Pharmacology (2018). The complete primary report is identified by DOI 10.1097/FBP.0000000000000409. Its value for forensic science lies partly in showing why dose, biological matrix, sampling time, task, and experimental design cannot be treated as interchangeable evidence.

What is the specific scientific question?

The experiment asks whether an amphetamine dose that changes performance in the five-choice serial reaction-time procedure can be related to circulating drug exposure. That is a useful preclinical question. It is different from asking whether the concentration reported by a forensic laboratory proves that a motorist was impaired at a particular time. The investigators measured food-reinforced signal detection in rats and, in a different set of rats, drug in plasma. They did not observe driving, reconstruct incidents, or classify individual humans as impaired.

The central result is conditional rather than categorical. At one injected dose, accuracy improved at several sampling times. At a higher injected dose, accuracy initially deteriorated, then improved later. If an expert compresses those results into the statement that amphetamine “improves attention” or “causes impairment” at a fixed concentration, the expert discards the very time-dependent contrast that makes the experiment informative.

How many animals were actually studied?

Eleven distinct male Sprague–Dawley rats contributed to two separate parts of the project. Six animals performed the behavioral procedure. Five additional animals supplied plasma samples for drug measurement. The six repeatedly completed test sessions under several dose-and-time conditions; the five provided a series of samples after one dose. Repeated trials and blood collections do not enlarge either independent biological sample.

This separation is a decisive inferential limitation. The study did not simultaneously obtain a contemporaneous amphetamine concentration and an accuracy score from the same rat. Rather, the authors aligned a behavioral time course from one cohort with a concentration time course from another. Their resulting exposure–performance depiction is useful as a group-level experimental comparison, but it cannot demonstrate a within-individual concentration–effect relationship, much less the prediction error of a human forensic classifier.

Which drug, route, and dose were used?

The test substance was d-amphetamine sulfate, administered by intraperitoneal injection. Behavioral doses were 0.1, 0.3, 1.0, and 1.7 mg/kg, expressed by the authors as the salt rather than free-base-equivalent milligrams. The plasma cohort received the 1.0 mg/kg injected dose. These numbers are not oral prescription doses, blood concentrations, or values suitable for direct human dose conversion.

Drug identity also matters. D-amphetamine is not methamphetamine, even though both belong to the broader stimulant family. It is also not a complete description of a mixed amphetamine-salts preparation or the prodrug lisdexamfetamine. A medicolegal analysis must establish the actual identified compound and, when consequential, the enantiomer and formulation. Substituting one for another by name alone risks a scientifically false comparison.

What exactly did the attention task measure?

The six behaviorally tested rats learned to respond to a briefly illuminated aperture among five possible locations. An appropriate nose poke could produce a food pellet. Testing used trained, food-restricted animals and a defined operant chamber, with trials ending according to preprogrammed response and reinforcement rules. A session ended after either 50 pellet presentations or 40 minutes.

The principal accuracy outcome was the percentage of correct selections among correct plus incorrect responses. The researchers also recorded omitted trials, latency from signal onset to a response, and responses during the intertrial interval. These endpoints are related but not synonymous: a missed signal, a delayed response, a wrong aperture, and an interval response represent different components of task performance. A rise in accuracy need not mean every other component improved.

Most importantly, this apparatus is not a road-driving simulator and does not measure field sobriety, lane position, collision avoidance, divided attention in traffic, or a validated legal impairment outcome. It gives a precisely operationalized measure of signal detection under highly controlled conditions.

When did the behavioral testing occur?

The investigators evaluated performance at multiple intervals after injection, including 5, 15, 30, 60, 120, and 240 minutes. The Methods section describes two determinations at five minutes, which were pooled because they were not statistically different. Several doses were studied at each delay, generally with repeated determinations in the same animal. The elapsed times therefore describe experimental post-injection intervals, not observed last-use times in an unknown case.

Time is essential to the result because the higher dose did not produce the same direction of effect throughout observation. A fixed nominal dose could first be associated with worsened responding and later with improved accuracy. It would be unsound to extrapolate that sequence into a universal clock for a person whose oral dose, prior exposure, health, drug combination, and sample matrix may be unknown.

What happened at the lower and intermediate doses?

At 0.1 and 0.3 mg/kg, the source describes relatively little change across the measured behavioral endpoints. That statement should not be inflated into proof that every low exposure has zero biological effect; limited statistical power and the tested task constrain it. Nor does it establish that these doses are safe for human driving. They are simply not the dose conditions producing the principal accuracy findings in this particular set of six rats.

At 1.0 mg/kg, the percentage of correct choices increased significantly at 30, 60, and 120 minutes following injection, with source-reported corrected comparisons below p = .05. The overall time-by-dose interaction in accuracy was reported as F(20,100) = 7.75, p < .001. These are group statistics derived from repeated observations, not an accuracy prediction for any one rat at a measured plasma concentration.

Why did the higher dose produce opposite effects at different times?

At 1.7 mg/kg, accuracy was significantly lower at 15 and 30 minutes, while the later 60- and 120-minute comparisons showed significantly higher accuracy. The early decrement coincided with more omitted trials at 5, 15, and 30 minutes and longer response latency at 15 and 30 minutes. The study therefore supplies concrete evidence against treating all stimulant-related behavioral changes as simple improvement in vigilance.

Early slowing and omission may interfere with successful task completion even if another component of processing is affected differently. Conversely, the later accuracy increase occurred without significant changes in those omission and latency measures. This does not prove that a specific neural mechanism caused the early decline: the endpoints demonstrate performance patterns, not a complete mechanistic attribution. It also does not supply plasma concentrations for the 1.7 mg/kg group, because the pharmacokinetic cohort was dosed at 1.0 mg/kg.

What significant and nonsignificant findings belong in the same account?

Selective citation of the beneficial accuracy observations would obscure the detrimental high-dose findings and the null outcomes. The researchers reported significant dose-and-time effects on accuracy, omissions, and latency, but no statistically significant change in intertrial-interval responses at any tested dose and time. They did not provide a single universal null p-value for that latter statement, so one should not invent one. Nor were the effects of 0.1 and 0.3 mg/kg described as reliable enhancements.

The overall repeated-measures statistics were F(20,100) = 7.75 for accuracy, 5.70 for omissions, and 11.59 for response latency, each reported p < .001. The table separates the prespecified behaviors and tested times rather than merging them into a single label such as “intoxication.”

Was one missing data point treated as an observed result?

No. At 1.7 mg/kg and the 15-minute assessment, one rat omitted every trial. Because correct choices among attempted choices cannot be calculated in the usual way when no choices occurred, the investigators used an expectation-maximization method to estimate that animal’s performance for repeated-measures analysis. The modeled entry is not a direct observation of a zero-percent correct result, and it cannot be presented in testimony as such.

Missingness matters particularly when it occurs in the most behaviorally disruptive condition. The method permits a repeated-measures analysis but introduces a modeling assumption about an unobserved value. Reanalysis without imputation, raw trial records, and sensitivity analyses would be relevant if a contested conclusion depended on the precise magnitude of that early high-dose comparison. The published result does not furnish a basis to reconstruct such missing raw behavior.

Which biological specimen was chemically analyzed?

The five pharmacokinetic animals provided approximately 0.2 mL blood samples collected retro-orbitally after the injected 1.0 mg/kg dose. Investigators centrifuged those specimens and removed plasma for analysis. This is a measurement of d-amphetamine in separated rat plasma, not a concentration determined directly in unseparated blood. The specimen was neither venous whole blood from a human nor a breath, oral-fluid, urine, or hair specimen.

The study used liquid chromatography–mass spectrometry in selected-ion monitoring mode, with labeled d8-amphetamine serving as internal standard. Amphetamine-related monitored ions included m/z 136 and 119, while labeled internal-standard ions included m/z 144 and 127. The reported calibration was linear from 10 to 500 ng/mL, with a 10 ng/mL limit of quantification. These analytical details give a defined context for what the laboratory measured. They do not certify comparability to every modern clinical or forensic assay.

What were the actual plasma concentrations and their timing?

The pharmacokinetic sampling schedule began at 15 minutes, with further sampling at 30, 60, 120, 240, and 360 minutes. The highest observed group concentration occurred at the earliest sampled time, 15 minutes, and values declined thereafter. Since no earlier samples were collected, the experiment cannot establish whether the true underlying concentration peak occurred before 15 minutes. Sampling time is not necessarily the same thing as the precise biological peak time.

In the comparison of the separate time courses, plasma values corresponding to significantly improved 1.0 mg/kg behavioral accuracy ranged from approximately 44.20 (± 6.87) to 102.14 (± 10.76) ng/mL. At about four hours, the study describes approximately 11.92 (± 3.97) ng/mL, when the accuracy improvement was no longer apparent. These are the source-reported summary values; they are not a validated prediction band for every animal or an individualized threshold for clinical function.

Near a quantification limit, analytical uncertainty and potentially nonquantifiable specimens deserve attention. The source’s reported four-hour summary approaches its stated 10 ng/mL LOQ. Neither that point nor the earlier range can be treated as a statutory concentration cutoff for someone else. A source-specific assay calibration range does not provide a validated conversion into whole blood from another species.

Why is the exposure–response plot not a personal drug-level prediction?

A pharmacokinetic/pharmacodynamic illustration can align average drug concentration over time with average behavioral effects over time. Such a display is useful for hypothesis generation, including the possibility that the same nominal dose yields changing functional outcomes as exposure rises or falls. It does not necessarily reveal how much variation exists between individual organisms. Here the concentration and task observations came from different rats, preventing a within-rat concentration-versus-performance regression.

The original publication refers to a hysteresis plot. That term describes a concentration–effect path through time; it is not, by itself, proof of a particular causal delay, acute tolerance mechanism, or legal impairment threshold. A plotted trajectory may reflect changing exposure, different behavioral measures, dosing route, adaptation, and multiple unmeasured processes. The original discussion itself treated acute tolerance as an open possibility rather than as an experimentally established mechanism.

Can these rat plasma numbers be converted into human whole-blood cutoffs?

No validated conversion is supplied. Rat plasma obtained after intraperitoneal administration differs from a forensic sample of human venous whole blood taken after a reported oral medication or suspected illicit administration. A plasma-to-whole-blood ratio requires data appropriate to the analyte, experimental conditions, species, sample handling, and assay. Neither species scaling nor a general rule-of-thumb provides a reliable substitute for such validation.

The article’s discussion compares its rat results with previously published human clinical plasma measurements in patients treated for ADHD. Those are other investigators’ cohorts, not additional human participants in this study. Therapeutic symptom improvement, laboratory signal-detection scores, and a chemical concentration also represent different endpoints. Similar numeric plasma ranges across species are not proof of identical receptor effects, identical individual function, or a defensible human legal threshold.

What would a scientifically justified forensic application require?

A case-specific evaluation starts with the actual specimen, chain of custody, analyte identity, assay validation, units, detection and quantification limits, collection time, and known or uncertain administration history. If legal whole-blood analysis is required, a plasma result must not be mislabeled as whole blood. The laboratory’s measurement uncertainty, calibration, handling, and any applicable statutory definition of specimen should remain explicit. A prescription record can establish access or intended dosing, not the concentration present at the relevant event.

Even when a competent laboratory establishes exposure, effect remains a separate question. Independent evidence of behavior, observations, medical factors, fatigue, coexposures, chronology, and alternative explanations may be relevant. This animal report does not supply the diagnostic sensitivity or specificity for intoxication, a person-specific impairment probability, or a validated individual threshold. Its most defensible forensic contribution is methodological caution about inferring performance from a single concentration.

Which uncertainties matter before extrapolating this experiment?

First, the experimental groups were small: six in behavior and five in pharmacokinetics. Second, behavior was measured repeatedly within animals, so repeated observations do not remedy the small count of independently sampled organisms. Third, those two groups differed in food restriction: behavioral subjects were food-restricted around sessions, while pharmacokinetic animals had unrestricted food access. Differences in husbandry and physiology can complicate interpretation of separate time courses.

Fourth, the intraperitoneal route and sulfate salt formulation are not necessarily equivalent to human oral or other exposures. Fifth, the published numeric summaries do not identify every individual response or supply an internally validated diagnostic classifier. Sixth, the authors examined only a narrow food-reinforced attention task, not comprehensive cognition or risk-taking. Seventh, limitations near the drug assay’s quantification boundary constrain fine distinctions at low plasma values.

Finally, the full original source supports the stated numerical observations but does not permit reconstruction of unseen plot points, exact individual plasma trajectories, or supplemental analyses not provided. Each of these limitations is a reason to describe the demonstrated experiment accurately rather than assign it broader courtroom authority than its design supports.

Frequently asked questions

1. Does 44–102 ng/mL mean amphetamine improves a person’s attention?

No. That approximate range came from chemically measured rat plasma in five animals aligned with a different six-rat attention experiment. The authors did not establish a human concentration–response threshold, and the cited benefit concerned a single food-reinforced signal-selection measure rather than universal attention or safe driving.

2. Were eleven rats each given both a blood test and an attention test?

No. Six animals underwent repeated operant behavioral testing, and five other animals provided serial plasma samples. It would be wrong to report eleven paired drug-and-behavior observations or to imply the study calculated individual correlations between both outcomes.

3. Did the highest tested dose always make the rats more accurate?

No. At 1.7 mg/kg the rats showed significantly worse accuracy at 15 and 30 minutes, alongside omission and latency changes; at 60 and 120 minutes, the measured accuracy contrast was better. The shifting direction of the findings is the opposite of a universal dose-only rule.

4. Does the study establish that low doses had no effects?

It reported relatively little change for 0.1 and 0.3 mg/kg, and no significant intertrial-interval responding effects for any dose. A nonsignificant finding in six rats is not proof of zero biological action under every possible circumstance. The source offers no universal threshold for a person.

5. Were the reported amphetamine values whole blood or plasma?

They were measured in plasma after centrifugation of blood from five rats. The original protocol used LC–MS with a labeled internal standard and a 10 ng/mL quantification limit. These concentrations should never be described as contemporaneous human forensic venous whole-blood results.

6. Does a four-hour concentration of roughly 12 ng/mL prove the drug was ineffective?

No. Around 240 minutes after 1.0 mg/kg, improved accuracy was no longer evident, while the separate pharmacokinetic cohort had a source-reported average near 11.92 ng/mL. That is a group observation near the assay’s quantification limit, not an individualized conclusion that all pharmacological effects have ended.

7. Can the study establish when a driver took amphetamine or whether it caused a collision?

No. There were no human participants, driving tests, real-world incidents, or matched human drug-and-behavior observations. Such an inference would need different, case-specific evidence and appropriate validation; it cannot be obtained by transferring a rat plasma time course directly into an individual legal opinion.

Evidence-based conclusion

The data show that d-amphetamine altered a rat attention procedure in a strongly dose- and time-dependent manner. Significant accuracy improvement at one dose and selected times coexisted with high-dose early deterioration, omission and latency effects, and an intertrial-interval null result. Separate LC–MS analysis quantified amphetamine in rat plasma and provided a time-course comparison, not a paired individual exposure–performance validation. The findings are useful for understanding a preclinical model and for recognizing the limits of concentration-based inference. They cannot establish a human whole-blood cutoff, a particular individual’s impairment, the timing of last use, or the cause of a traffic or other disputed event.

Primary empirical source: Slezak JM, Mueller M, Ricaurte GA, Katz JL. Pharmacokinetic and pharmacodynamic analysis of d-amphetamine in an attention task in rodents. Behavioural Pharmacology. 2018;29(6):551–556. Original scientific publication and DOI.